Michael Davin

As Cynosure’s Chairman, President, and Chief Executive Officer from 2003 to 2017, Michael Davin oversaw sales growth from $20 million to $430 million, including significant international expansion, led the company’s initial public offering and listing on the NASDAQ, and executed key acquisitions. Under his leadership, Cynosure achieved compound annual revenue growth of more than 20 percent and became one of the largest and most profitable companies in the aesthetic industry. Cynosure was sold to Hologic for $1.65 billion in March 2017.